← Back to Search

Vitamin C for Cardiovascular Risk

N/A

Waitlist Available

Led By Saurabh S Thosar, PhD

Research Sponsored by Oregon Health and Science University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately three months

Awards & highlights

Study Summary

This trial will study whether Vitamin C can help reduce morning cardiovascular risk markers. The study will be double blind, meaning that neither the participants nor the researchers will know who is taking Vitamin C or the placebo until the study is over.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately three months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately three months

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately three months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Oxidative stress

Plasma Vitamin C and Tetrahydrobiopterin

Vascular Endothelial Function

Secondary outcome measures

Plasminogen activator inhibitor -1

Platelet aggregation

Side effects data

From 2018 Phase 2 trial • 20 Patients • NCT03148236

10%

Pericarditis

100%

80%

60%

40%

20%

Study treatment Arm

Vitamin C

Placebo

Trial Design

2Treatment groups

Experimental Treatment

Group I: Vitamin C then PlaceboExperimental Treatment2 Interventions

Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.

Group II: Placebo then Vitamin CExperimental Treatment2 Interventions

Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vitamin C

2017

Completed Phase 4

~18470

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor

973 Previous Clinical Trials

6,846,019 Total Patients Enrolled

6 Trials studying Cardiovascular Risk

1,672 Patients Enrolled for Cardiovascular Risk

Saurabh S Thosar, PhDPrincipal InvestigatorOregon Health and Science University

2 Previous Clinical Trials

144 Total Patients Enrolled

2 Trials studying Cardiovascular Risk

144 Patients Enrolled for Cardiovascular Risk

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is the ideal target population for inclusion in this trial?

"To qualify for this medical experiment, applicants must display cardiovascular risk and be within the range of 40 to 60 years old. Enrollment is limited to 10 participants in total."

Answered by AI

Are octogenarians eligible to join the research project?

"Individuals aged between 40 and 60 are eligible for this trial. There are 3 seperate medical studies available to patients under 18 years of age, while those over 65 can participate in 66 different clinical trials."

Answered by AI

Are participants being actively recruited for this clinical inquiry?

"Unfortunately, the clinicaltrial.gov records demonstrate that this trial is not presently enrolling patients; however, it was posted in 2018 and last updated in 2022. Luckily, there are 82 other trials actively recruiting at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vitamin C to Reduce Morning Cardiovascular Risk

Steven A. Shea 2018. "Vitamin C to Reduce Morning Cardiovascular Risk". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03290612.